[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563987":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":12,"centralContacts":37,"locations":47,"responsibleParty":79,"collaborators":12,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":31,"eligibilityCriteria":88,"healthyVolunteers":84,"sex":89,"minAge":12,"maxAge":90,"enrollmentInfo":91,"targetDuration":12,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":104,"whyStopped":12,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"Medical College of Wisconsin","OTHER",[8,13,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Control Arm","NO_INTERVENTION","Prospective data review of patients who did not receive light therapy",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Prevention Arm","ACTIVE_COMPARATOR","Prospective data review of patients who did receive light therapy",[18],"Device: Photobiomodulation for prevention arm",{"label":20,"type":15,"description":21,"interventionNames":22},"Exploratory Arm","Prospective review of patients with Trisomy 21 who did receive light therapy",[23],"Device: Photobiomodulation for exploratory arm",[25,33],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DEVICE","Photobiomodulation for prevention arm","Light therapy will be administered using the cluster probe on the external cheeks bilaterally and intraorally using the lollipop probe for patients ≥7 years of age. Patients \\\u003C7 years of age will not receive intraoral treatment with the lollipop. Instead, they will be asked to open their mouth while the covered cluster probe is held externally to treat their intraoral membranes. Each treatment (both external cheeks and intraoral buccal region) will be administered over 1 min with a Modulation Frequency 2.5Hz, Skin Conduction nS 001, and Beam Power mW 000, for a total treatment time of 3 minutes.\n\nPatients will continue to receive light therapy in the home setting through day +8 of their chemotherapy cycle using the Luminance Device.",[14],[31,32],"PBM","Light therapy",{"type":26,"name":34,"description":28,"armGroupLabels":35,"otherNames":36},"Photobiomodulation for exploratory arm",[20],[31,32],[38,43],{"name":39,"role":40,"phone":41,"phoneExt":12,"email":42},"Elissa Shulta, DNP","CONTACT","414-266-5407","EShulta@childrenswi.org",{"name":44,"role":40,"phone":45,"phoneExt":12,"email":46},"Peter Shaw, MD","414-955-4086","pshaw@mcw.edu",[48],{"facility":5,"status":12,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Milwaukee","Wisconsin","53226","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-87.90647,43.0389,{"lat":58,"lon":57},[61,62,63,65,67,69,71,73,75,77],{"name":39,"role":40,"phone":41,"phoneExt":12,"email":42},{"name":44,"role":40,"phone":45,"phoneExt":12,"email":46},{"name":44,"role":64,"phone":12,"phoneExt":12,"email":12},"SUB_INVESTIGATOR",{"name":66,"role":64,"phone":12,"phoneExt":12,"email":12},"Valerie Lohse, MSN",{"name":68,"role":64,"phone":12,"phoneExt":12,"email":12},"Sarah Joost, MSN",{"name":39,"role":70,"phone":12,"phoneExt":12,"email":12},"PRINCIPAL_INVESTIGATOR",{"name":72,"role":64,"phone":12,"phoneExt":12,"email":12},"Meredith Beversdorf, BSN",{"name":74,"role":64,"phone":12,"phoneExt":12,"email":12},"Amberley Kemic, BSN",{"name":76,"role":64,"phone":12,"phoneExt":12,"email":12},"Ashley Hain, BSN",{"name":78,"role":64,"phone":12,"phoneExt":12,"email":12},"Amy Pan, PhD",{"type":70,"investigatorFullName":80,"investigatorTitle":81,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"Elissa Shulta","Principal Investigator","100563987","a-clinical-trial-of-the-administration-of-light-therapy-to-prevent-mouth-sores-in-children-with-cancer-100563987",false,"NCT06623305","A Clinical Trial of the Administration of Light Therapy to Prevent Mouth Sores in Children With Cancer","Photobiomodulation Therapy for the Prevention of Mucositis in Pediatric Oncology Patients","Inclusion Criteria:\n\n1. Current and new diagnosis patients consented upon admission if deemed eligible\n2. Ages 0-30\n3. Admitted to CW oncology\u002FBMT inpatient unit, PICU, or West 5\n4. Chemotherapy regimen: Methotrexate ≥5 g\u002Fm2 (or ≥1 g\u002Fm2 if Trisomy 21) OR Anthracycline ≥60 mg\u002Fm2\n5. Able to speak and understand English or Spanish\n\nExclusion Criteria:\n\n1. Patients admitted on BMT service\n2. Patients currently experiencing mucositis with a CTCAE grade 4 oral mucositis or higher","ALL","30 Years",{"count":92,"type":93},50,"ESTIMATED","INTERVENTIONAL",[96],"NA","The goal of this clinical trial is to learn if light therapy can prevent mouth sores in children with cancer. The main questions it aims to answer are:\n\nIs it reasonable and acceptable to provide light therapy for children with cancer?\n\nDoes light therapy prevent mouth sores related to medical treatment?\n\nResearchers will compare children who do not receive light therapy to children who do receive light therapy during the clinical trial to see if light therapy helps to prevent mucositis.\n\nParticipants will:\n\n* Complete a survey.\n* Have picture taken of their mouth to look for mouth sores.\n* Receive light therapy every day while admitted to the hospital on the cancer unit or while admitted to an alternate unit, and continue to receive light therapy in the home setting until they reach 8 days after the start of their chemotherapy cycle.",[99],"Mucositis Oral",[101,102,103],"Photobiomodulation","Mucositis","Oral Mucositis","NOT_YET_RECRUITING","2026-06-16",{"date":107,"type":108},"2026-06-22","ACTUAL",{"date":110,"type":93},"2026-08",{"date":112,"type":93},"2027-09",{"name":5,"class":6},1]